Q2
CODX — Q2 2026 Financial Report Analysis
Co-Diagnostics sold just $0.17M of PCR tests in Q2 2026 against a $6.3M net loss; cash fell to $3.6M, the 10-Q carries a going-concern warning, and the company is funding itself by issuing shares while it awaits FDA review of its point-of-care PCR device.